

AmCham Shanghai Capstone Conference Healthcare Industry Highlights

Greg Scott, Chair, Healthcare Committee



Healthcare Industry: 2019 vs 2020

2019 was a strong year for healthcare MNCs in China:

- 86% of surveyed* healthcare companies had top line growth
- 81% were profitable
- 71% grew faster in China than globally
- 100% planned to maintain or increase China investment

 But the headwinds of 2020 slowing industry growth in China:
- 52% estimated first half 2020 China revenue down
- 29% planned to decrease China investment
- #1 reason for negative impact: Coronavirus (77%)

^{*}Source: 2020 China Business Report, AmCham Shanghai (based on a survey of AmCham member companies)



VC Investment, IPOs and Cross-border Partnering


- VC investment has returned to 2018 levels, on track to reach a record \$18B+ in 2020
 - 60% of cross-border investments with the US
- Therapeutics (pharma/biotech) largest segment (35%), following by iHealth (25%)
- IPOs forecasted to hit a record \$10B+ in new company value
- Partnering (e.g., licensing, co-development) could reach nearly \$30B
 - >80% cross-border deals
 - Average deal size a record \$250M


Source: State of China Life Science: 2020 H1, ChinaBio® Consulting

Majority of cross-border VC investments still with US; EU gaining in outbound investment from China



Cross-border VC/PE Life Science Investment






In-bound


US still most desirable region for cross border partnering with China healthcare companies



Pharma Partnering by Region



Source: State of China Life Science: 2020 H1, ChinaBio® Consulting





Major Trends Identified by AmCham HC Committee

- Shift from crisis response to establishing a "new normal" to leveraging opportunities
- Rapid digitization of the healthcare industry